Subjects:
Free Research Articles
On pages 4930, 4931, and 4932 in the 13 December 2012 issue, there are typesetting errors in Tables 1, 2, and 3, respectively. In Tables 1, 2, and 3, two entries under the “Mean BMI at blood draw, kg/m2 (SD)” heading contain typographical errors. The incorrect entries read “<18.5-25, N (%)” and “<25-30, N (%).” These two entries should have read, “18.5-<25, N (%)” and “25-<30, N (%),” respectively. The corrected Tables 1, 2, and 3 are shown.
Table 1
Selected characteristics of the study population by cohort (pooled, ATBC, and HPFS)
| . | Pooled . | ATBC31 . | HPFS30 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 493 | 978 | 46 | 92 | 29 | 58 |
| Mean age at blood draw, y (SD) | 63.3 (7.1) | 63.3 (7.2) | 58.6 (4.7) | 58.5 (4.7) | 62.7 (9.4) | 62.6 (9.5) |
| Sex, N (%) | ||||||
| Male | 172 (34.9) | 344 (35.2) | 46 (100) | 92 (100) | 29 (100) | 58 (100) |
| Female | 321 (65.1) | 634 (64.8) | NA | NA | NA | NA |
| Race, N (%) | ||||||
| White | 432 (87.6) | 860 (87.9) | 46 (100) | 92 (100) | 26 (89.7) | 55 (94.8) |
| Black | 32 (6.5) | 62 (5.3) | NA | NA | 1 (3.5) | NA |
| Asian | 12 (2.4) | 25 (2.6) | NA | NA | NA | NA |
| Other | 17 (3.4) | 31 (3.2) | NA | NA | 2 (6.9) | 3 (5.2) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (5.2) | 27.2 (5.0) | 26.7 (2.8) | 26.2 (3.8) | 26.3 (3.3) | 26.0 (3.2) |
| <18.5, N (%) | 2 (0.4) | 8 (0.8) | NA | NA | 9 (31.0) | 24 (41.4) |
| 18.5-<25, N (%) | 163 (33.1) | 342 (35.0) | 10 (21.7) | 37 (40.2) | 15 (51.7) | 27 (46.6) |
| 25-<30, N (%) | 215 (43.6) | 406 (41.5) | 29 (63.0) | 42 (45.7) | 4 (13.8) | 4 (6.9) |
| 30+, N (%) | 110 (22.3) | 212 (21.7) | 7 (15.2) | 13 (14.1) | 1 (3.5) | 3 (5.2) |
| Missing, N (%) | 3 (0.6) | 10 (1.0) | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | 70 (14.2) | 140 (14.3) | 46 (100) | 92 (100) | NA | NA |
| Plasma, heparin | 200 (40.6) | 392 (40.1) | NA | NA | NA | NA |
| Plasma, EDTA | 202 (41.0) | 404 (41.3) | NA | NA | 29 (100) | 58 (100) |
| Plasma, sodium citrate | 21 (4.3) | 42 (4.3) | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 354 (71.8) | 709 (72.5) | 39 (84.8) | 78 (84.8) | 21 (72.4) | 42 (72.4) |
| Not fasting | 139 (28.2) | 269 (27.5) | 7 (15.2) | 14 (15.2) | 8 (27.6) | 16 (27.6) |
| Mean blood draw to diagnosis, y (range) | 6.6 (0.3-18.1) | 6.5 (−0.5 to 18.2) | 9.8 (1.3-18.1) | 9.8 (1.3-18.2) | 6.6 (0.5-12.2) | 6.6 (0.4-12.3) |
| ≤3, N (%) | 92 (18.7) | 170 (17.9) | 4 (8.7) | 8 (8.7) | 8 (28.6) | 15 (27.3) |
| 4-≤6, N (%) | 150 (30.6) | 303 (31.8) | 10 (21.7) | 18 (19.6) | 5 (17.9) | 10 (18.2) |
| >6, N (%) | 249 (50.7) | 479 (50.3) | 32 (69.6) | 66 (71.7) | 15 (53.6) | 30 (54.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 150 (52.5) | 146.4 (49.4) | 170.3 (38.7) | 150.9 (44.5) | 189.6 (49.2) | 168.8 (46.2) |
| IGFBP-3, ng/mL | 4 490 (1 203) | 4 423 (1 170) | 3 859 (941) | 3 402 (1 053) | 4 531 (1 110) | 4 267 (991) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.2 (0.04) | 0.2 (0.03) | 0.2 (0.03) | 0.1 (0.02) |
| IGFBP-1, ng/mL | 32.2 (24.9) | 30.3 (32.3) | 21.9 (14.9) | 25.2 (14.7) | 34.9 (29.5) | 28.8 (19.9) |
| C-peptide, ng/mL | 2.1 (1.5) | 2.1 (1.6) | 1.9 (0.8) | 1.7 (1.1) | 2.4 (1.1) | 2.6 (1.6) |
| CRP, mg/L | 3.5 (5.6) | 3.7 (5.8) | 4.1 (6.8) | 4.2 (8.3) | 1.7 (1.6) | 1.3 (1.4) |
| IL-6, pg/mL | 2.2 (2.3) | 2.5 (4.5) | 3.0 (2.9) | 3.7 (5.5) | 1.7 (1.5) | 1.5 (1.2) |
| sIL6R, pg/mL | 41 871 (15 713) | 39 278 (10 923) | 36 502 (9 674) | 36 318 (8 881) | 43 084 (15 111) | 36 087 (8 244) |
| . | Pooled . | ATBC31 . | HPFS30 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 493 | 978 | 46 | 92 | 29 | 58 |
| Mean age at blood draw, y (SD) | 63.3 (7.1) | 63.3 (7.2) | 58.6 (4.7) | 58.5 (4.7) | 62.7 (9.4) | 62.6 (9.5) |
| Sex, N (%) | ||||||
| Male | 172 (34.9) | 344 (35.2) | 46 (100) | 92 (100) | 29 (100) | 58 (100) |
| Female | 321 (65.1) | 634 (64.8) | NA | NA | NA | NA |
| Race, N (%) | ||||||
| White | 432 (87.6) | 860 (87.9) | 46 (100) | 92 (100) | 26 (89.7) | 55 (94.8) |
| Black | 32 (6.5) | 62 (5.3) | NA | NA | 1 (3.5) | NA |
| Asian | 12 (2.4) | 25 (2.6) | NA | NA | NA | NA |
| Other | 17 (3.4) | 31 (3.2) | NA | NA | 2 (6.9) | 3 (5.2) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (5.2) | 27.2 (5.0) | 26.7 (2.8) | 26.2 (3.8) | 26.3 (3.3) | 26.0 (3.2) |
| <18.5, N (%) | 2 (0.4) | 8 (0.8) | NA | NA | 9 (31.0) | 24 (41.4) |
| 18.5-<25, N (%) | 163 (33.1) | 342 (35.0) | 10 (21.7) | 37 (40.2) | 15 (51.7) | 27 (46.6) |
| 25-<30, N (%) | 215 (43.6) | 406 (41.5) | 29 (63.0) | 42 (45.7) | 4 (13.8) | 4 (6.9) |
| 30+, N (%) | 110 (22.3) | 212 (21.7) | 7 (15.2) | 13 (14.1) | 1 (3.5) | 3 (5.2) |
| Missing, N (%) | 3 (0.6) | 10 (1.0) | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | 70 (14.2) | 140 (14.3) | 46 (100) | 92 (100) | NA | NA |
| Plasma, heparin | 200 (40.6) | 392 (40.1) | NA | NA | NA | NA |
| Plasma, EDTA | 202 (41.0) | 404 (41.3) | NA | NA | 29 (100) | 58 (100) |
| Plasma, sodium citrate | 21 (4.3) | 42 (4.3) | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 354 (71.8) | 709 (72.5) | 39 (84.8) | 78 (84.8) | 21 (72.4) | 42 (72.4) |
| Not fasting | 139 (28.2) | 269 (27.5) | 7 (15.2) | 14 (15.2) | 8 (27.6) | 16 (27.6) |
| Mean blood draw to diagnosis, y (range) | 6.6 (0.3-18.1) | 6.5 (−0.5 to 18.2) | 9.8 (1.3-18.1) | 9.8 (1.3-18.2) | 6.6 (0.5-12.2) | 6.6 (0.4-12.3) |
| ≤3, N (%) | 92 (18.7) | 170 (17.9) | 4 (8.7) | 8 (8.7) | 8 (28.6) | 15 (27.3) |
| 4-≤6, N (%) | 150 (30.6) | 303 (31.8) | 10 (21.7) | 18 (19.6) | 5 (17.9) | 10 (18.2) |
| >6, N (%) | 249 (50.7) | 479 (50.3) | 32 (69.6) | 66 (71.7) | 15 (53.6) | 30 (54.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 150 (52.5) | 146.4 (49.4) | 170.3 (38.7) | 150.9 (44.5) | 189.6 (49.2) | 168.8 (46.2) |
| IGFBP-3, ng/mL | 4 490 (1 203) | 4 423 (1 170) | 3 859 (941) | 3 402 (1 053) | 4 531 (1 110) | 4 267 (991) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.2 (0.04) | 0.2 (0.03) | 0.2 (0.03) | 0.1 (0.02) |
| IGFBP-1, ng/mL | 32.2 (24.9) | 30.3 (32.3) | 21.9 (14.9) | 25.2 (14.7) | 34.9 (29.5) | 28.8 (19.9) |
| C-peptide, ng/mL | 2.1 (1.5) | 2.1 (1.6) | 1.9 (0.8) | 1.7 (1.1) | 2.4 (1.1) | 2.6 (1.6) |
| CRP, mg/L | 3.5 (5.6) | 3.7 (5.8) | 4.1 (6.8) | 4.2 (8.3) | 1.7 (1.6) | 1.3 (1.4) |
| IL-6, pg/mL | 2.2 (2.3) | 2.5 (4.5) | 3.0 (2.9) | 3.7 (5.5) | 1.7 (1.5) | 1.5 (1.2) |
| sIL6R, pg/mL | 41 871 (15 713) | 39 278 (10 923) | 36 502 (9 674) | 36 318 (8 881) | 43 084 (15 111) | 36 087 (8 244) |
Percentages and counts may not sum to the total because of rounding and/or missing data.
NA indicates not applicable.
Table 2
Selected characteristics of the study population by cohort (MCCS, NHS, and PLCO)
| . | MCCS23 . | NHS22,25 . | PLCO26 . | |||
|---|---|---|---|---|---|---|
| . | Cases . | Controls . | Cases . | Controls . | Cases . | Controls . |
| No. of persons | 55 | 110 | 39 | 71 | 96 | 192 |
| Mean age at blood draw, y (SD) | 59.5 (7.4) | 59.5 (7.4) | 59.4 (6.0) | 58.3 (5.9) | 63.9 (5.2) | 63.8 (5.0) |
| Sex, N (%) | ||||||
| Male | 31 (56.4) | 62 (56.4) | NA | NA | 60 (62.5) | 120 (62.5) |
| Female | 24 (43.6) | 48 (43.6) | 39 (100) | 71 (100) | 36 (37.5) | 72 (37.5) |
| Race, N (%) | ||||||
| White | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 87 (90.6) | 174 (90.6) |
| Black | NA | NA | NA | NA | 4 (4.2) | 8 (4.2) |
| Asian | NA | NA | NA | NA | 2 (2.1) | 4 (2.1) |
| Other | NA | NA | NA | NA | 3 (3.1) | 6 (3.1) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (4.2) | 26.8 (3.9) | 26.1 (4.7) | 25.4 (4.5) | 28.4 (6.0) | 27.5 (4.7) |
| <18.5, N (%) | 1 (1.8) | NA | 1 (2.6) | NA | NA | 2 (1.0) |
| 18.5-<25, N (%) | 16 (29.1) | 38 (34.6) | 16 (41.0) | 36 (50.7) | 27 (28.1) | 53 (27.6) |
| 25-<30, N (%) | 24 (43.6) | 50 (45.5) | 14 (35.9) | 20 (28.2) | 41 (42.7) | 95 (49.5) |
| 30+, N (%) | 14 (25.5) | 22 (20.0) | 6 (15.4) | 10 (14.1) | 28 (29.2) | 40 (20.8) |
| Missing, N (%) | NA | NA | 2 (5.1) | 5 (7.0) | NA | 2 (1.0) |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | NA | NA | NA | NA |
| Plasma, heparin | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 96 (100) | 192 (100) |
| Plasma, EDTA | NA | NA | NA | NA | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 42 (76.4) | 84 (76.4) | 27 (69.2) | 56 (78.9) | NA | NA |
| Not fasting | 13 (23.6) | 26 (23.6) | 12 (30.8) | 15 (21.1) | 96 (100) | 193 (100) |
| Mean blood draw to diagnosis, y (range) | 8.2 (1.1-16.8) | 8.2 (1.2-16.8) | 9.4 (1.5-16.0) | 9.8 (2.8-16.1) | 6.4 (1.2-12.3) | 6.4 (1.2-12.5) |
| ≤3, N (%) | 6 (10.9) | 10 (9.1) | 2 (5.3) | 1 (1.9) | 9 (9.4) | 17 (8.9) |
| 4-≤6, N (%) | 14 (25.5) | 30 (27.3) | 6 (15.8) | 10 (18.9) | 37 (38.5) | 75 (39.1) |
| >6, N (%) | 35 (63.6) | 70 (63.6) | 30 (79.0) | 42 (79.3) | 50 (52.1) | 100 (52.1) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 158.9 (52.9) | 161.5 (50.2) | 151.5 (51.2) | 151.3 (47.4) | 159.9 (58.5) | 158.1 (52.0) |
| IGFBP-3, ng/mL | 4 777 (1 404) | 4 872 (1 170) | 5 300 (1 299) | 5 327 (1 293) | 4 708 (1 285) | 4 660 (1 069) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.02) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 34.4 (23.6) | 25.4 (15.2) | 20.9 (13.1) | 24.4 (15.4) | N/A | N/A |
| C-peptide, ng/mL | 1.7 (1.2) | 1.5 (0.8) | 2.2 (1.4) | 2.5 (1.7) | 2.8 (1.8) | 3.0 (2.5) |
| CRP, mg/L | 3.1 (7.8) | 2.3 (3.0) | 2.6 (3.8) | 2.8 (3.9) | 3.4 (4.8) | 3.7 (6.0) |
| IL-6, pg/mL | 1.7 (1.4) | 2.4 (3.6) | 2.2 (2.9) | 1.6 (1.5) | 2.3 (1.7) | 2.4 (2.3) |
| sIL6R, pg/mL | 42 252 (11 293) | 41 908 (10 234) | 42 793 (10 563) | 40 909 (10 879) | 43 495 (11 683) | 41 909 (10 816) |
| . | MCCS23 . | NHS22,25 . | PLCO26 . | |||
|---|---|---|---|---|---|---|
| . | Cases . | Controls . | Cases . | Controls . | Cases . | Controls . |
| No. of persons | 55 | 110 | 39 | 71 | 96 | 192 |
| Mean age at blood draw, y (SD) | 59.5 (7.4) | 59.5 (7.4) | 59.4 (6.0) | 58.3 (5.9) | 63.9 (5.2) | 63.8 (5.0) |
| Sex, N (%) | ||||||
| Male | 31 (56.4) | 62 (56.4) | NA | NA | 60 (62.5) | 120 (62.5) |
| Female | 24 (43.6) | 48 (43.6) | 39 (100) | 71 (100) | 36 (37.5) | 72 (37.5) |
| Race, N (%) | ||||||
| White | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 87 (90.6) | 174 (90.6) |
| Black | NA | NA | NA | NA | 4 (4.2) | 8 (4.2) |
| Asian | NA | NA | NA | NA | 2 (2.1) | 4 (2.1) |
| Other | NA | NA | NA | NA | 3 (3.1) | 6 (3.1) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (4.2) | 26.8 (3.9) | 26.1 (4.7) | 25.4 (4.5) | 28.4 (6.0) | 27.5 (4.7) |
| <18.5, N (%) | 1 (1.8) | NA | 1 (2.6) | NA | NA | 2 (1.0) |
| 18.5-<25, N (%) | 16 (29.1) | 38 (34.6) | 16 (41.0) | 36 (50.7) | 27 (28.1) | 53 (27.6) |
| 25-<30, N (%) | 24 (43.6) | 50 (45.5) | 14 (35.9) | 20 (28.2) | 41 (42.7) | 95 (49.5) |
| 30+, N (%) | 14 (25.5) | 22 (20.0) | 6 (15.4) | 10 (14.1) | 28 (29.2) | 40 (20.8) |
| Missing, N (%) | NA | NA | 2 (5.1) | 5 (7.0) | NA | 2 (1.0) |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | NA | NA | NA | NA |
| Plasma, heparin | 55 (100) | 110 (100) | 39 (100) | 71 (100) | 96 (100) | 192 (100) |
| Plasma, EDTA | NA | NA | NA | NA | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 42 (76.4) | 84 (76.4) | 27 (69.2) | 56 (78.9) | NA | NA |
| Not fasting | 13 (23.6) | 26 (23.6) | 12 (30.8) | 15 (21.1) | 96 (100) | 193 (100) |
| Mean blood draw to diagnosis, y (range) | 8.2 (1.1-16.8) | 8.2 (1.2-16.8) | 9.4 (1.5-16.0) | 9.8 (2.8-16.1) | 6.4 (1.2-12.3) | 6.4 (1.2-12.5) |
| ≤3, N (%) | 6 (10.9) | 10 (9.1) | 2 (5.3) | 1 (1.9) | 9 (9.4) | 17 (8.9) |
| 4-≤6, N (%) | 14 (25.5) | 30 (27.3) | 6 (15.8) | 10 (18.9) | 37 (38.5) | 75 (39.1) |
| >6, N (%) | 35 (63.6) | 70 (63.6) | 30 (79.0) | 42 (79.3) | 50 (52.1) | 100 (52.1) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 158.9 (52.9) | 161.5 (50.2) | 151.5 (51.2) | 151.3 (47.4) | 159.9 (58.5) | 158.1 (52.0) |
| IGFBP-3, ng/mL | 4 777 (1 404) | 4 872 (1 170) | 5 300 (1 299) | 5 327 (1 293) | 4 708 (1 285) | 4 660 (1 069) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.02) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 34.4 (23.6) | 25.4 (15.2) | 20.9 (13.1) | 24.4 (15.4) | N/A | N/A |
| C-peptide, ng/mL | 1.7 (1.2) | 1.5 (0.8) | 2.2 (1.4) | 2.5 (1.7) | 2.8 (1.8) | 3.0 (2.5) |
| CRP, mg/L | 3.1 (7.8) | 2.3 (3.0) | 2.6 (3.8) | 2.8 (3.9) | 3.4 (4.8) | 3.7 (6.0) |
| IL-6, pg/mL | 1.7 (1.4) | 2.4 (3.6) | 2.2 (2.9) | 1.6 (1.5) | 2.3 (1.7) | 2.4 (2.3) |
| sIL6R, pg/mL | 42 252 (11 293) | 41 908 (10 234) | 42 793 (10 563) | 40 909 (10 879) | 43 495 (11 683) | 41 909 (10 816) |
Percentages and counts may not sum to the total because of rounding and/or missing data.
NA indicates not applicable.
Table 3
Selected characteristics of the study population by cohort (SCHS, WHI, and WHS)
| . | SCHS24,27 . | WHI32 . | WHS29 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 10 | 19 | 197 | 394 | 21 | 42 |
| Mean age at blood draw, y (SD) | 66.5 (6.6) | 66.4 (6.7) | 66.4 (6.5) | 66.5 (6.5) | 58.7 (6.9) | 58.6 (6.7) |
| Sex, N (%) | ||||||
| Male | 6 (60.0) | 12 (63.2) | NA | NA | NA | NA |
| Female | 4 (40.0) | 7 (36.8) | 197 (100) | 394 (100) | 21 (100) | 42 (100) |
| Race, N (%) | ||||||
| White | NA | NA | 160 (81.2) | 320 (81.2) | 19 (90.5) | 38 (90.5) |
| Black | NA | NA | 26 (13.2) | 52 (13.2) | 1 (4.8) | 2 (4.8) |
| Asian | 10 (100) | 19 (100) | NA | NA | NA | 2 (4.8) |
| Other | NA | NA | 11 (5.6) | 22 (5.6) | 1 (4.8) | NA |
| Mean BMI at blood draw, kg/m2 (SD) | 23.7 (2.6) | 23 (3.0) | 27.8 (5.7) | 28.2 (5.7) | 25.7 (4.1) | 26.6 (4.4) |
| <18.5, N (%) | NA | 2 (10.5) | NA | 4 (1.0) | NA | NA |
| 18.5-<25, N (%) | 8 (80.0) | 11 (57.9) | 66 (33.5) | 128 (32.5) | 11 (52.4) | 15 (35.7) |
| 25-<30, N (%) | 2 (20.0) | 6 (31.6) | 82 (41.6) | 146 (37.1) | 8 (38.1) | 20 (47.6) |
| 30+, N (%) | NA | NA | 49 (24.9) | 116 (29.4) | 2 (9.5) | 7 (16.7) |
| Missing, N (%) | NA | NA | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | 24 (12.2) | 48 (12.2) | NA | NA |
| Plasma, heparin | 10 (100) | 19 (100) | NA | NA | NA | NA |
| Plasma, EDTA | NA | NA | 173 (87.8) | 346 (87.8) | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | 21 (100) | 42 (100) |
| Fasting status, N (%) | ||||||
| Fasting | 10 (100) | 19 (100) | 197 (100) | 394 (100) | 18 (85.7) | 36 (85.7) |
| Not fasting | NA | NA | NA | NA | 3 (14.3) | 6 (14.3) |
| Mean blood draw to diagnosis, y (range) | 2.5 (0.3-5.2) | 2.5 (0.2-5.1) | 5.2 (0.5-11.1) | 5.2 (-0.5-11.3) | 6.1 (2.2-9.8) | 6.1 (2.2-9.8) |
| ≤3, N (%) | 6 (60.0) | 11 (57.9) | 51 (25.9) | 98 (25.2) | 6 (28.6) | 10 (23.8) |
| 4-≤6, N (%) | 4 (40.0) | 8 (42.1) | 69 (35.0) | 140 (36.0) | 5 (23.8) | 12 (28.6) |
| >6, N (%) | NA | NA | 77 (39.1) | 151 (38.8) | 10 (47.6) | 20 (47.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 136.2 (43.9) | 133.2 (44.1) | 136.5 (48.5) | 133.2 (46.7) | 112.4 (31.4) | 134.7 (43.5) |
| IGFBP-3, ng/mL | 4 456 (1 213) | 4 356 (1 427) | 4 356 (1 059) | 4 313 (1 046) | 3 825 (744) | 4 152 (901) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 71.0 (47.0) | 64.0 (137.9) | 33.2 (24.7) | 32.0 (26.6) | 31.0 (14.6) | 28.2 (26.3) |
| C-peptide, ng/mL | 5.7 (5.6) | 5.1 (2.2) | 1.7 (0.8) | 1.7 (0.8) | 2.0 (1.1) | 2.1 (1.1) |
| CRP, mg/L | 1.0 (1.2) | 1.2 (1.9) | 3.9 (5.3) | 4.5 (6.4) | 4.7 (8.7) | 3.7 (4.8) |
| IL-6, pg/mL | 2.4 (2.1) | 1.9 (2.0) | 2.2 (2.6) | 2.7 (5.8) | NA | NA |
| sIL6R, pg/mL | 65 025 (70 369) | 30 364 (6 864) | 40 665 (12 232) | 38 537 (11 544) | NA | NA |
| . | SCHS24,27 . | WHI32 . | WHS29 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 10 | 19 | 197 | 394 | 21 | 42 |
| Mean age at blood draw, y (SD) | 66.5 (6.6) | 66.4 (6.7) | 66.4 (6.5) | 66.5 (6.5) | 58.7 (6.9) | 58.6 (6.7) |
| Sex, N (%) | ||||||
| Male | 6 (60.0) | 12 (63.2) | NA | NA | NA | NA |
| Female | 4 (40.0) | 7 (36.8) | 197 (100) | 394 (100) | 21 (100) | 42 (100) |
| Race, N (%) | ||||||
| White | NA | NA | 160 (81.2) | 320 (81.2) | 19 (90.5) | 38 (90.5) |
| Black | NA | NA | 26 (13.2) | 52 (13.2) | 1 (4.8) | 2 (4.8) |
| Asian | 10 (100) | 19 (100) | NA | NA | NA | 2 (4.8) |
| Other | NA | NA | 11 (5.6) | 22 (5.6) | 1 (4.8) | NA |
| Mean BMI at blood draw, kg/m2 (SD) | 23.7 (2.6) | 23 (3.0) | 27.8 (5.7) | 28.2 (5.7) | 25.7 (4.1) | 26.6 (4.4) |
| <18.5, N (%) | NA | 2 (10.5) | NA | 4 (1.0) | NA | NA |
| 18.5-<25, N (%) | 8 (80.0) | 11 (57.9) | 66 (33.5) | 128 (32.5) | 11 (52.4) | 15 (35.7) |
| 25-<30, N (%) | 2 (20.0) | 6 (31.6) | 82 (41.6) | 146 (37.1) | 8 (38.1) | 20 (47.6) |
| 30+, N (%) | NA | NA | 49 (24.9) | 116 (29.4) | 2 (9.5) | 7 (16.7) |
| Missing, N (%) | NA | NA | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | NA | NA | 24 (12.2) | 48 (12.2) | NA | NA |
| Plasma, heparin | 10 (100) | 19 (100) | NA | NA | NA | NA |
| Plasma, EDTA | NA | NA | 173 (87.8) | 346 (87.8) | NA | NA |
| Plasma, sodium citrate | NA | NA | NA | NA | 21 (100) | 42 (100) |
| Fasting status, N (%) | ||||||
| Fasting | 10 (100) | 19 (100) | 197 (100) | 394 (100) | 18 (85.7) | 36 (85.7) |
| Not fasting | NA | NA | NA | NA | 3 (14.3) | 6 (14.3) |
| Mean blood draw to diagnosis, y (range) | 2.5 (0.3-5.2) | 2.5 (0.2-5.1) | 5.2 (0.5-11.1) | 5.2 (-0.5-11.3) | 6.1 (2.2-9.8) | 6.1 (2.2-9.8) |
| ≤3, N (%) | 6 (60.0) | 11 (57.9) | 51 (25.9) | 98 (25.2) | 6 (28.6) | 10 (23.8) |
| 4-≤6, N (%) | 4 (40.0) | 8 (42.1) | 69 (35.0) | 140 (36.0) | 5 (23.8) | 12 (28.6) |
| >6, N (%) | NA | NA | 77 (39.1) | 151 (38.8) | 10 (47.6) | 20 (47.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 136.2 (43.9) | 133.2 (44.1) | 136.5 (48.5) | 133.2 (46.7) | 112.4 (31.4) | 134.7 (43.5) |
| IGFBP-3, ng/mL | 4 456 (1 213) | 4 356 (1 427) | 4 356 (1 059) | 4 313 (1 046) | 3 825 (744) | 4 152 (901) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) | 0.1 (0.03) |
| IGFBP-1, ng/mL | 71.0 (47.0) | 64.0 (137.9) | 33.2 (24.7) | 32.0 (26.6) | 31.0 (14.6) | 28.2 (26.3) |
| C-peptide, ng/mL | 5.7 (5.6) | 5.1 (2.2) | 1.7 (0.8) | 1.7 (0.8) | 2.0 (1.1) | 2.1 (1.1) |
| CRP, mg/L | 1.0 (1.2) | 1.2 (1.9) | 3.9 (5.3) | 4.5 (6.4) | 4.7 (8.7) | 3.7 (4.8) |
| IL-6, pg/mL | 2.4 (2.1) | 1.9 (2.0) | 2.2 (2.6) | 2.7 (5.8) | NA | NA |
| sIL6R, pg/mL | 65 025 (70 369) | 30 364 (6 864) | 40 665 (12 232) | 38 537 (11 544) | NA | NA |
Percentages and counts may not sum to the total because of rounding and/or missing data.
NA indicates not applicable.
2014
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal